On July 28, 2026, ClinicalTrials.gov listed an update for the study titled "A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET." The trial, registered under identifier NCT05050942, is a Phase 3 study. Its current status is active, not recruiting. This means the trial is ongoing but is no longer enrolling new participants.
Lanreotide is an approved compound, and this trial update concerns octreotide subcutaneous depot rather than lanreotide directly. Readers following lanreotide developments may find this study relevant given both compounds are somatostatin analogs used in related indications, including gastroenteropancreatic neuroendocrine tumors (GEP-NET).
No results, efficacy data, or safety findings have been reported as part of this status update. The listing reflects only the trial's phase and recruitment status as of the given date. No additional details about trial design, endpoints, or outcomes were included in this update.
For more background on lanreotide, including its approved uses and general profile, see the compound overview.